Q4 2024 Earnings Call Transcript February 28, 2025 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is $0.04, ...

Fulgent Genetics exceeded expectations in the fourth quarter of 2024, showcasing robust revenue growth and a GAAP loss.

Gabbi’s telehealth solution provides logistics and educational support to assess breast cancer risk. Patients identified as potentially high risk are connected with a Gabbi clinician to be evaluated ...

UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective dropped by investment analysts at UBS Group from ...

FDA Fast Track Designation granted for Phentolamine Ophthalmic Solution 0.75% as treatment of significant chronic night ...

Emerging technologies, such as remote tonometry and genetic risk scoring, are revolutionizing glaucoma care by enabling ...

NIMS Medical Genetics department in Hyderabad offers cutting-edge diagnostic and therapeutic services for rare genetic ...

StockNews.com lowered shares of Myriad Genetics (NASDAQ:MYGN – Free Report) from a buy rating to a hold rating in a research ...

A new approach reveals genetic interactions that contribute to heart defects. Scientists at the Icahn School of Medicine at ...

In response to a recent reader inquiry regarding the degree of heterosis he could expect in his breeding program, we thought ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a collaboration with Gabbi, a ...